Patient Communication and Radiation Safety in [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy: International Survey of 102 Theranostic Centers
Journal of Nuclear Medicine · 05.11.2026 · jnumed.126.273336
DOI: 10.2967/jnumed.126.273336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 05.11.2026. Verfasst von Josef Zahner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
[177Lu]Lu-PSMA radiopharmaceutical therapy (RPT) is increasingly administered worldwide in both inpatient and outpatient settings. Despite its growing use, there is no harmonized international guidance on what patients should be told before, during, and after therapy. This study aimed to capture current clinical practice and expert opinion to identify areas of consensus and divergence to develop a patient information template.
Methods
An international survey was conducted among theranostic centers performing [177Lu]Lu-PSMA RPT. The questionnaire covered pretreatment procedures, therapy procedures, radiation precautions guidance, and posttreatment procedures. Inpatient and outpatient settings were evaluated separately.
Results
In total, 102 centers from 23 countries participated. High agreement was observed for most pretreatment procedures, core therapy aspects, and general posttreatment guidance. In contrast, substantial variability was identified in posttreatment radiation precautions, particularly regarding distancing measures, duration of precautions, transportation after discharge, household and hygiene recommendations, and guidance affecting social interactions.
Conclusion
This international survey demonstrated broad consensus for core clinical procedures but showed variability in posttreatment radiation precautions after RPT. By summarizing current practice and translating it into a patient information template, this project supports more consistent patient guidance across diverse clinical settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; lena.unterrainer@mri.tum.de.
- Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine, UCLA, Los Angeles, California.
- Nuclear Medicine with a Specialization in Translational Theranostics, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Nuclear Medicine Division, Medical Imaging Department, Gustave Reussy, Paris-Saclay University, Orsay, France.
- BioMaps Multimodal Biomedical Imaging Laboratory, INSERM UMR 1281, CNRS UMR90, CEA, Paris-Saclay University, Orsay, France.
Zitieren
APA
Zahner, J., Unterrainer, L. M., Czernin, J., Calais, J., Eiber, M., Fendler, W. P., Werner, R. A., Gardner, L., Allen-Auerbach, M., & Benz, M. R. (2026). Patient Communication and Radiation Safety in [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy: International Survey of 102 Theranostic Centers. Journal of Nuclear Medicine, jnumed.126.273336. https://doi.org/10.2967/jnumed.126.273336
Vancouver
Zahner J, Unterrainer LM, Czernin J, Calais J, Eiber M, Fendler WP, et al. Patient Communication and Radiation Safety in [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy: International Survey of 102 Theranostic Centers. Journal of Nuclear Medicine. 2026:jnumed.126.273336. doi:10.2967/jnumed.126.273336
BibTeX
@article{Zahner2026,
author = {Zahner, Josef and Unterrainer, Lena M and Czernin, Johannes and Calais, Jeremie and Eiber, Matthias and Fendler, Wolfgang P and Werner, Rudolf A and Gardner, Linda and Allen-Auerbach, Martin and Benz, Matthias R},
title = {Patient Communication and Radiation Safety in [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy: International Survey of 102 Theranostic Centers},
journal = {Journal of Nuclear Medicine},
year = {2026},
pages = {jnumed.126.273336},
doi = {10.2967/jnumed.126.273336}
}
EUVIMED